Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Galectin Therapeutics Inc. (GALT) had Debt to Equity Ratio of -0.99 for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-8.22M |
|
-- |
|
-- |
|
$4.20M |
|
$-4.20M |
|
$-3.99M |
|
$-8.18M |
|
$-8.18M |
|
$-8.18M |
|
$-8.18M |
|
$-8.18M |
|
$-8.18M |
|
$-4.20M |
|
$-4.20M |
|
64.20M |
|
64.20M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$12.73M |
|
-- |
|
$0.14M |
|
$12.87M |
|
$136.44M |
|
-- |
|
-- |
|
$136.44M |
|
$-125.79M |
|
$-123.58M |
|
$-123.58M |
|
64.47M |
|
| Cash Flow Statement Financials | |
$-17.83M |
|
-- |
|
$14.24M |
|
$15.12M |
|
$11.53M |
|
$-3.60M |
|
$1.46M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.09 |
|
-- |
|
-- |
|
-- |
|
|
Debt to Equity Ratio |
-0.99 |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-17.83M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
6.51% |
|
6.62% |
|
-63.61% |
|
6.62% |
|
$-1.92 |
|
$-0.28 |
|
$-0.28 |
|